Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives $32.29 Average Target Price from Analysts

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWNGet Free Report) has received a consensus rating of “Buy” from the eight analysts that are currently covering the stock, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $32.29.

A number of equities research analysts have recently commented on DAWN shares. JPMorgan Chase & Co. dropped their price objective on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 5th. Needham & Company LLC restated a “buy” rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday. Bank of America cut their price target on Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Finally, Wedbush reiterated an “outperform” rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th.

Get Our Latest Stock Analysis on DAWN

Insider Activity at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, General Counsel Adam Dubow sold 4,646 shares of Day One Biopharmaceuticals stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $55,566.16. Following the sale, the general counsel now owns 39,602 shares of the company’s stock, valued at $473,639.92. The trade was a 10.50 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Charles N. York II sold 4,370 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $52,265.20. Following the completion of the sale, the chief financial officer now owns 252,638 shares of the company’s stock, valued at $3,021,550.48. This trade represents a 1.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 21,064 shares of company stock valued at $251,925. 8.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC acquired a new stake in shares of Day One Biopharmaceuticals in the fourth quarter valued at approximately $866,000. Charles Schwab Investment Management Inc. increased its stake in shares of Day One Biopharmaceuticals by 14.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 507,448 shares of the company’s stock worth $7,069,000 after acquiring an additional 64,700 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its holdings in shares of Day One Biopharmaceuticals by 90.6% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 121,167 shares of the company’s stock worth $1,535,000 after acquiring an additional 57,601 shares during the period. Geode Capital Management LLC raised its holdings in shares of Day One Biopharmaceuticals by 10.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,432,697 shares of the company’s stock worth $19,961,000 after acquiring an additional 136,458 shares during the period. Finally, Erste Asset Management GmbH acquired a new position in shares of Day One Biopharmaceuticals during the 3rd quarter valued at about $725,000. 87.95% of the stock is owned by hedge funds and other institutional investors.

Day One Biopharmaceuticals Stock Performance

NASDAQ:DAWN opened at $7.22 on Wednesday. The firm’s fifty day moving average is $10.13 and its two-hundred day moving average is $12.40. The firm has a market cap of $731.78 million, a price-to-earnings ratio of -7.01 and a beta of -1.38. Day One Biopharmaceuticals has a one year low of $7.06 and a one year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWNGet Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.34). The firm had revenue of $29.21 million during the quarter, compared to analysts’ expectations of $27.11 million. As a group, equities research analysts predict that Day One Biopharmaceuticals will post -0.72 earnings per share for the current fiscal year.

Day One Biopharmaceuticals Company Profile

(Get Free Report

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.

Further Reading

Analyst Recommendations for Day One Biopharmaceuticals (NASDAQ:DAWN)

Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.